Bretylium tosylate

Base Information

• Chemical Name: Bretylium tosylate
• CAS No.: 61-75-6
• Molecular Formula: C11H17BrN•C7H7O3S
• Molecular Weight: 414.363
• Hs Code.: 2923900100
• European Community (EC) Number: 200-516-8
• NSC Number: 62164
• UNII: 78ZP3YR353
• DSSTox Substance ID: DTXSID1022685
• Wikidata: Q27105972
• NCI Thesaurus Code: C47418
• ChEMBL ID: CHEMBL1095292
• Mol file: 61-75-6.mol

Synonyms:Bretylate;Bretylium Tosilate;Bretylium Tosylate;Bretylol;Ornid

Chemical Property of Bretylium tosylate

Chemical Property:

• Melting Point: 97-99°
• PSA: 65.58000
• LogP: 5.02530
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility.: H2O: soluble50mg/mL
• Hydrogen Bond Donor Count: 0
• Hydrogen Bond Acceptor Count: 3
• Rotatable Bond Count: 3
• Exact Mass: 413.06603
• Heavy Atom Count: 24
• Complexity: 349

Purity/Quality:

99% ^*data from raw suppliers

Bretylium tosylate ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xn
• Hazard Codes: Xn
• Statements: 20/21/22
• Safety Statements: 36

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: CC[N+](C)(C)CC1=CC=CC=C1Br.CC1=CC=C(C=C1)S(=O)(=O)[O-]
• Uses: Bretylium tosylate has a biphasic response, initially inducing norepinephrine release followed by sympathetic ganglionic blockade. Bretylium tosylate is a class III antiarrhythmic agent and a competitive inhibitor of acetylcholinesterase.
• Therapeutic Function: Adrenergic blocker; Antiarrhythmic
• Clinical Use: Currently, bretylium is reserved for use in ventriculararrhythmias that are resistant to other therapy. Bretyliumdoes not suppress phase 4 depolarization, a common actionof other antiarrhythmic agents. It prolongs the effectiverefractory period relative to the action potential durationbut does not affect conduction time and is categorized asa class III antiarrhythmic agent. Because bretylium doesnot have properties similar to those of the other antiarrhythmicagents, it has been suggested that its action is aresult of its adrenergic neuronal-blocking properties; theantiarrhythmic properties of the drug, however, are notaffected by administration of reserpine. Bretylium is also alocal anesthetic, but it has not been possible to demonstratesuch an effect on atria of experimental animals, except atvery high concentrations. Therefore, the precise mechanismof the antiarrhythmic action of bretylium remains tobe resolved.

Technology Process of Bretylium tosylate

There total 1 articles about Bretylium tosylate which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

2-bromo-N,N-dimethylbenzylamine (1976-04-1) + ethyl ester of p-toluenesulfonic acid (80-40-0) → bretylium tosylate (61-75-6)

Guidance literature:

In acetone; for 12h; Reflux;

upstream raw materials:

2-bromo-N,N-dimethylbenzylamine

ethyl ester of p-toluenesulfonic acid

Refernces